Updated:
Helixmith
Helixmith (KOSDAQ: 084990) is a biotechnology company founded in 1996 in Seoul, South Korea. It develops gene therapies, biopharmaceuticals, novel biologics,...
Overview
Helixmith (KOSDAQ: 084990) is a biotechnology company founded in 1996 in Seoul, South Korea. It develops gene therapies, biopharmaceuticals, novel biologics, and herbal therapeutics for diseases such as diabetic foot ulcers, claudication, and amyotrophic lateral sclerosis. The company offers solutions for previously untreated conditions.
General information
Firm type
Asset Manager
Location
Region
Asia
Country
South Korea
City
Seoul
Corporate office
Seoul, South Korea
Frequently asked questions
What can be confirmed about Helixmith's investment focus?
Nothing. Helixmith's website is gated behind a human-verification process that blocks automated research tools. No primary-source interviews, regulatory filings, or published investor letters have surfaced to confirm its strategy, sector preferences, or asset-class exposure.
Who runs Helixmith?
That is unknown. The firm's website, protected behind a bot-detection gate, is the only accessible public source, and it does not reveal team rosters, founder names, or leadership titles on indexed pages. No alternative primary source fills this gap.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: